Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Interparfums (NASDAQ:IPAR – Get Free Report) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Volatility and Risk
Niagen Bioscience has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Institutional & Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 55.6% of Interparfums shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Comparatively, 43.6% of Interparfums shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Niagen Bioscience and Interparfums”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 1.29 | $17.38 million | $0.12 | 17.50 |
| Interparfums | $1.49 billion | 2.87 | $168.39 million | $5.31 | 25.08 |
Interparfums has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Niagen Bioscience and Interparfums, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Interparfums | 1 | 5 | 2 | 0 | 2.12 |
Niagen Bioscience currently has a consensus target price of $8.50, suggesting a potential upside of 304.76%. Interparfums has a consensus target price of $125.29, suggesting a potential downside of 5.93%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Interparfums.
Profitability
This table compares Niagen Bioscience and Interparfums’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| Interparfums | 11.33% | 15.43% | 10.99% |
Summary
Interparfums beats Niagen Bioscience on 10 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes. Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.
About Interparfums
Interparfums, Inc. develops, markets and distributes prestige fragrances and related beauty products. Its offerings include perfumes, colognes and fragrance-related products created with fashion, luxury and lifestyle brands. Founded in 1982 by Jean Madar and Philippe Benacin, the company has built a portfolio through licensing agreements and brand ownership. Its fragrance brands have included Coach, Jimmy Choo, Montblanc and Lacoste; its portfolio can change as licensing agreements begin or end.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
